Advertisement
Screener

MeiraGTx Holdings plc (MGTX) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest

2.7 / 5 stars · 39/72 Roast Me

MeiraGTx Holdings plc Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest

MeiraGTx Holdings plc (MGTX) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $215.78 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-13

  • 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $215.78M.
  • 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$58.13M.
  • 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$5.79M.
  • 2025-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $2.96M.
Period endStockholders' Equity, Including Portion Attributable to Noncontrolling Interest
2026-06-30$215.78M
10-Q · filed 2026-08-13
2026-03-31-$58.13M
10-Q · filed 2026-08-13
2025-12-31-$5.79M
10-Q · filed 2026-08-13
2025-06-30$2.96M
10-Q · filed 2026-08-13
2025-03-31$33.10M
10-Q · filed 2026-08-13
2024-12-31$67.83M
10-Q · filed 2026-08-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10